
Gataparsen

Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.
It being investigated for a number of different cancers.
It is targeted at survivin which prevents cells dying.
Clinical trials.
It has completed a phase II trial for acute myeloid leukemia.
A phase II trial for non-small cell lung cancer has started.
A phase II trial for hormone-refractory prostate cancer will run until early 2012.